Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access & Reimbursement

Set Alert for Market Access & Reimbursement

Latest From Market Access

Health Technology Assessments And the Trouble With Rare Disease Treatments

To get their gene or cell therapies through health technology appraisals, companies need to agree to gather longer-term evidence, be upfront about what treatments can really deliver and remember to ask for patient input.

Europe Health Technology Assessment

Only One In Seven PRIME Applications Meet EMA Test

Of the 14 applications for entry onto the European Medicines Agency’s priority medicines scheme during the first two months of 2019, only two – from AstraZeneca and Freeline – made the grade.
Europe Market Access

Part D Premiums ‘Won’t Go Up’ With HHS Rebate Proposal, Azar Maintains

US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.

Medicare Reimbursement

Novartis Strikes Kymriah Outcome-Based Deal With German Insurers

Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.

Europe Germany

Drug Pricing And The Trump Effect: How To Make A High Profile Hearing Vanish

Without President Trump’s focus on drug pricing, it is hard to imagine that seven top industry executives would have had to face a grilling in the US Senate Finance Committee. But they can also thank Trump’s indiscretions for helping ensure that the hearing was barely even a one-day story.

 

Pricing Debate Reimbursement

ICER's Review Of Rebate Reform, At A Glance

The Institute for Clinical and Economic Review has weighed in on the pros and cons of rebate reform, surveying an assortment of payers, pharmacy benefit managers and pharmaceutical companies on alternative rebate models and their potential impact.  
Pharmacy Benefit Management Pricing Debate
See All
UsernamePublicRestriction

Register